15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $15M | -$64M | 0.0% | -251.6% | -$19M | — | $41M |
| 2024 | $9M | -$19M | 96.5% | -226.1% | -$24M | — | $46M |
| 2023 | $9M | -$21M | 92.5% | -276.5% | -$29M | — | $35M |
| 2022 | $15M | -$26M | 95.0% | -153.2% | $646000 | — | $11M |
| 2021 | $4M | -$43M | 67.2% | -1133.6% | -$24M | — | $56M |
| 2020 | $2M | -$21M | 78.9% | -1448.4% | -$20M | — | $33M |
| 2019 | $4M | -$12M | 88.3% | -1106.0% | -$32M | — | $9M |
| 2018 | $5M | -$46M | 93.9% | -837.9% | -$31M | — | $24M |
| 2017 | $3M | -$20M | 95.1% | -1125.0% | -$32M | — | $37M |
| 2016 | — | $34M | — | — | -$45M | — | $22M |
| 2015 | — | -$47M | — | — | -$46M | — | $42M |
| 2014 | — | -$36M | — | — | — | — | $29M |
| 2013 | — | -$44M | — | — | -$32M | — | $5M |
| 2012 | — | -$21M | — | — | -$20M | — | $4M |
| 2011 | — | -$17M | — | — | -$15M | — | $22M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2M | -$5M | 0.0% | -440.2% | -$8M | — | $36M |
| Dec '25 | $7M | $851000 | 0.0% | -99.1% | -$5M | — | $41M |
| Sep '25 | $4M | -$30M | 0.0% | -102.9% | -$4M | — | $40M |
| Jun '25 | $3M | -$30M | 0.0% | -715.4% | -$6M | — | $42M |
| Mar '25 | $2M | -$4M | 97.6% | -433.1% | -$5M | — | $48M |
| Dec '24 | $3M | -$3M | 94.6% | -178.2% | -$7M | — | $46M |
| Sep '24 | $4M | -$3M | 99.0% | -101.6% | -$6M | — | $28M |
| Jun '24 | $1M | -$6M | 96.9% | -416.7% | -$5M | — | $30M |
| Mar '24 | $1M | -$7M | 93.2% | -461.3% | -$6M | — | $44M |
| Dec '23 | $2M | -$5M | 87.7% | -304.7% | -$6M | — | $35M |
| Sep '23 | $1M | -$7M | 86.4% | -538.1% | -$5M | — | $31M |
| Jun '23 | $3M | -$5M | 96.1% | -155.8% | -$7M | — | $34M |
| Mar '23 | $2M | -$4M | 95.0% | -278.4% | -$11M | — | $15M |
| Dec '22 | $2M | -$6M | 94.7% | -346.7% | -$8M | — | $11M |
| Sep '22 | $3M | -$6M | 92.2% | -175.2% | -$6M | — | $25M |
| Jun '22 | — | -$7M | — | — | -$7M | — | $71M |
| Mar '22 | — | -$7M | — | — | $22M | — | $78M |
| Dec '21 | — | -$29M | — | — | -$6M | — | $56M |
| Sep '21 | — | -$8M | — | — | — | — | $61M |
| Jun '21 | — | -$5M | — | — | -$6M | — | $62M |
How the market has priced LCTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Lineage Cell Therapeutics, Inc.'s revenue has grown 51.5% per year. These are computed facts, not advice.
As of FY2025, Lineage Cell Therapeutics, Inc. reported — of total debt against $41M of cash.
In FY2025, gross margin was —, operating margin -251.6%, and net margin -436.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.